Literature DB >> 25592045

Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.

David A Luckenbaugh1, Rezvan Ameli2, Nancy E Brutsche3, Carlos A Zarate4.   

Abstract

Although antidepressant trials typically use weekly ratings to examine changes in symptoms over six to 12 weeks, antidepressant treatments may improve symptoms more quickly. Thus, rating scales must be adapted to capture changes over shorter intervals. We examined the use of the 17-item Hamilton Depression Rating Scale (HDRS) to evaluate more rapid changes. Data were examined from 58 patients with major depressive disorder or bipolar disorder enrolled in double-blind, placebo-controlled, crossover studies who received a single infusion of ketamine (0.5 mg/kg) or placebo over 40 min then crossed over to the other condition. HDRS subscales, a single HDRS Depressed mood item, and a visual analogue scale were used at baseline, after a brief interval (230 min), and one week post-infusion. Effect sizes for the ketamine-placebo difference were moderate (d > 0.50), but one and two-item HDRS subscales had the smallest effects. Response rates on active drug were lowest for the complete HDRS (43%); the remaining scales had higher response rates to active drug, but the shortest subscales had higher response rates to placebo. Correlations between the changes from baseline to 230 min post-ketamine across scores were similar for most subscales (r = 0.82-0.97), but correlations using the single items were lower (r < 0.74). Overall, effect sizes for drug-placebo differences and correlations between changes were lower for one- and two-item measures. Response rates were lower with the full HDRS scale. The data suggest that, to best identify rapid antidepressant effects, a scale should have more than two items, but fewer items than a full scale. Published by Elsevier Ltd.

Entities:  

Keywords:  Antidepressant; Bipolar disorder; Depression; HDRS; Ketamine; Ratings

Mesh:

Substances:

Year:  2014        PMID: 25592045      PMCID: PMC4308518          DOI: 10.1016/j.jpsychires.2014.12.015

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  26 in total

1.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

2.  Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials.

Authors:  Ruud Boessen; Rolf H H Groenwold; Mirjam J Knol; Diederick E Grobbee; Kit C B Roes
Journal:  J Affect Disord       Date:  2012-09-07       Impact factor: 4.839

3.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

4.  HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

Authors:  P Bech; P Boyer; J-M Germain; K Padmanabhan; V Haudiquet; B Pitrosky; K A Tourian
Journal:  Pharmacopsychiatry       Date:  2010-09-09       Impact factor: 5.788

5.  Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.

Authors:  Craig H Mallinckrodt; Roy N Tamura; Yoko Tanaka
Journal:  J Psychiatr Res       Date:  2011-03-31       Impact factor: 4.791

6.  The responsiveness of the Hamilton Depression Rating Scale.

Authors:  D Faries; J Herrera; J Rayamajhi; D DeBrota; M Demitrack; W Z Potter
Journal:  J Psychiatr Res       Date:  2000 Jan-Feb       Impact factor: 4.791

7.  Assessing full remission.

Authors:  Roger McIntyre; Sidney Kennedy; R Michael Bagby; David Bakish
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

8.  Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy.

Authors:  Gijs Santen; Meindert Danhof; Oscar Della Pasqua
Journal:  J Psychiatr Res       Date:  2009-04-02       Impact factor: 4.791

9.  A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects.

Authors:  Richard Entsuah; Michelle Shaffer; Jun Zhang
Journal:  J Psychiatr Res       Date:  2002 Nov-Dec       Impact factor: 4.791

10.  Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos.

Authors:  Darcy A Santor; David Debrota; Nina Engelhardt; Steve Gelwicks
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

View more
  4 in total

1.  Mechanisms of Repetitive Transcranial Magnetic Stimulation on Post-stroke Depression: A Resting-State Functional Magnetic Resonance Imaging Study.

Authors:  Yamei Li; Kuide Li; Rongjian Feng; Yi Li; Yufeng Li; Hong Luo; Qian Yu
Journal:  Brain Topogr       Date:  2022-03-14       Impact factor: 3.020

2.  Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.

Authors:  Elizabeth D Ballard; David A Luckenbaugh; Erica M Richards; Tessa L Walls; Nancy E Brutsché; Rezvan Ameli; Mark J Niciu; Jennifer L Vande Voort; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2015-06-16       Impact factor: 4.791

3.  Discriminating Bipolar Disorder From Major Depression Based on SVM-FoBa: Efficient Feature Selection With Multimodal Brain Imaging Data.

Authors:  Nan-Feng Jie; Mao-Hu Zhu; Xiao-Ying Ma; Elizabeth A Osuch; Michael Wammes; Jean Théberge; Huan-Dong Li; Yu Zhang; Tian-Zi Jiang; Jing Sui; Vince D Calhoun
Journal:  IEEE Trans Auton Ment Dev       Date:  2015-10-26

4.  A novel method for evaluating brain function and microstructural changes in Parkinson's disease.

Authors:  Ming-Fang Jiang; Feng Shi; Guang-Ming Niu; Sheng-Hui Xie; Sheng-Yuan Yu
Journal:  Neural Regen Res       Date:  2015-12       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.